Dermatological adverse events from BRAF inhibitors: a growing problem.

Abstract excerpt

The development of targeted therapies has ushered in a new era in the management of melanoma. Inhibitors of the RAS-RAF-MEK-ERK pathway have taken the center stage with development at a rapid pace. Vemurafenib was recently approved by regulatory agencies, and other agents (e.g. dabrafenib) are in various stages of clinical testing. These agents are producing remarkable results for patients, but are also...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Eruptions
• Share to Indoles
• Share to MAP Kinase Signaling System